Last updated on April 2019

Efficacy and Safety Study of VB-1953 Topical Gel for Inflammatory Facial Acne Vulgaris


Brief description of study

A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Dose-ranging Study in the Treatment of Acne Vulgaris,

Detailed Study Description

This will be a Phase 2, multicenter, randomized, double-blinded, dose-ranging, parallel arm comparison study in male and non-pregnant female subjects, 9 through 45 years of age (inclusive) with facial acne vulgaris. This dose-ranging study, intended to identify the dose(s), will consist of 7 study visits over 14 weeks:

Clinical Study Identifier: NCT03900676

Find a site near you

Start Over

Vyome Therapeutics Inc.

La Jolla, CA United States
  Connect »

Vyome Therapeutics Inc.

Sherman Oaks, CA United States
  Connect »

Vyome Therapeutics Inc.

Brandon, FL United States
  Connect »

Vyome Therapeutics Inc.

Coral Gables, FL United States
  Connect »

Vyome Therapeutics Inc

Miami, FL United States
  Connect »

Vyome Therapeutics Inc.

Winter Park, FL United States
  Connect »

Vyome Therapeutics Inc.

High Point, NC United States
  Connect »

Vyome Therapeutics Inc.

Hazleton, PA United States
  Connect »

Vyome Therapeutics Inc.

Upper Saint Clair, PA United States
  Connect »

Vyome Therapeutics Inc.

Mount Pleasant, SC United States
  Connect »

Vyome Therapeutics Inc.

El Paso, TX United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.